Addition of commercial-scale sterile injectables capabilities in Lexington, KY.

Operational expansion accelerates global distribution capability to increase regional access and technical support. Multiple partnerships establish direct distribution channels in China, Japan, South Korea, Singapore and Israel.

Partnership Combines VERAXA’s Proprietary ADC Technology with OmniAb’s Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors.

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer.

Researchers and scientists must invest wisely in the tools they use and stay up-to-date with market trends. Cell counting is a demanding area, and you need instruments that are safe and easy to use. Standout counting or analysis tools will eliminate human error and guarantee consistent and fast results.